CURRICULUM VITAE

Celina G. Kleer, M.D.Page 1 of 23

Last updated: 4/8/2023

Curriculum Vitae

PERSONAL INFORMATION

Name: Celina G. Kleer, M.D.Birth Date: June 4, 1971Birth Place: Buenos Aires, ArgentinaNationality: U.S. Citizen

Work Address: University of Michigan, Department of Pathology3510 MSRB I, Ann Arbor, MI 48109-0605

Home Address: 4001 Calgary Ct.Ann Arbor, MI 48108

EDUCATION

3/1/1983-12/30/1987 High School: Carlos Pellegrini High School, Buenos Aires, Argentina

3/1/1988-12/30/1993 Medical School: University of Buenos Aires, School of Medicine, Buenos Aires, Argentina, MD degree.

1/1/1993-3/30/1993 Visiting Medical Student, Department of Physiology and Biophysics, Mayo Graduate School of Medicine, Mayo Clinic, Rochester, Minnesota

POSTDOCTORAL TRAINING

7/1/1994-6/30/1995 Pathology Resident, Anatomic and Clinical Pathology Mayo Clinic, Rochester, MN

7/1/1995-6/30/1998 Pathology Resident, Anatomic and Clinical Pathology University of Michigan, Ann Arbor, Michigan

7/1/1998-6/30/1999 Surgical Pathology Fellow, University of Michigan, Ann Arbor, Michigan

ACADEMIC APPOINTMENTS

7/1/1999-5/21/2005 Assistant Professor of PathologyUniversity of Michigan, Ann Arbor, Michigan

5/19/2005-present Associate Professor of Pathology, with tenureUniversity of Michigan, Ann Arbor, Michigan

2002- present Director, Breast Pathology Fellowship, University of Michigan

2006- present Director, Breast Pathology Program, University of Michigan

2007- present Harold A. Oberman Collegiate Professor of Pathology



SCIENTIFIC ACTIVITIES

Editorial Activities and Scientific Panels

2006- present Member of the Breast Cancer Panel on the CAP (College of American Pathologists) Cancer Committee

2007- present Member of the Editorial Board of Human Pathology2008 Moderator, Breast Pathology Session, United States and Canadian

Academy of Pathology Annual Meeting

Manuscript and Abstract Reviews

2000-Present Manuscript Reviewer, Breast Cancer Research and Treatment2001-Present Manuscript Reviewer, Cancer Research2001-Present Manuscript Reviewer, Modern Pathology2002-Present Manuscript Reviewer, Neoplasia2005-Present Manuscript Reviewer, Experimental Cell Research2006 Society for Molecular Imaging2006- United States and Canadian Academy of Pathology (IAP-USCAP)

Grant Reviews

2003-2004 Breast Alliance for Cancer Research2005 and 2007 Department of Defense Breast Cancer Research Program, Cell

Biology Study Section2006 Ad hoc reviewer, NIH National Institute of General Medical

Sciences, Minority Biomedical Research Excellence Program (MBRS)

2007 (June and Temporary member, NIH Tumor Progression and Metastasis Study October) Section (TMP)2008 (February) Ad Hoc reviewer, NIH Tumor Cell Biology Study Section (TCB)2008 (February) Ad Hoc reviewer, NIH Cancer Diagnostics and Treatments I

SBIR/STTR, Council ZRG1 Onc-L2008 (July) Ad Hoc reviewer, NIH Molecular Pathways in Cancer, ZRG1

ONC-X (03) M 2008- present Permanent member, NIH Tumor Progression and Metastasis Study

Section (TMP)2009 (June) Member, NIH ZRG1 OBT-A (58) R, and NIH ZRG1 OBT-S Study

Sections2009 Grant Reviewer, Association for International Cancer Research,

United Kingdom

GRANT SUPPORTActiveRO1 CA107469 (Kleer, C.G.) 2/01/05-1/31/10



NIH/NCI“Role of EZH2 in Breast Cancer Progression” To investigate the role of EZH2 in the development and progression of breast cancer.

N009672 Avon Foundation (Kleer, C.G.) 01/01/2008 - 12/31/2009“Enhancer of Zeste 2 as a Biomarker of Preneoplastic Progression in the breast”To determine the clinical utility of EZH2 in the detection of precancerous epithelial changes in the breast which may improve risk assessment and lead to novel preventative strategies.

R01CA125577 (Kleer, C.G.) 09/01/08 – 07/31/13NIH/NCI“Role of CCN6 (WISP3) in the Progression and Metastasis of Breast Cancer”To investigate the role of CCN6 in the process of epithelial to mesenchymal transition in breast cancer, study its effect on breast cancer metastasis, and its utility as a biomarker of breast cancer progression.

Post-doctoral fellowship grant to Anupama Pal 07/01/2008 – 12/31/2009Cancer Biology Training ProgramUniversity of Michigan (Kleer, C.G., mentor)“Understanding CCN6 (WISP3)’s function as a determinant of breast cancer metastasis”To study the role of CCN6 in invasion and metastasis of breast cancer using three dimensional culture models and by developing a conditional CCN6 knock out mouse model.

Recent

DAMD17-00-1-0636 (Kleer, C.G.) 9/15/00-9/14/02USAMRMC-Concept Award $75,000 0%"LIBC (Lost in Inflammatory Breast Cancer) Gene Targeted Mice: A Novel Model to Develop and Test Gene Targeted Therapies for Inflammatory Breast Cancer”

Research Grant (Kleer, C.G.) 8/1/01-7/31/03John and Suzanne Munn Endowed Research Fund of the $10,000 0%University of Michigan Comprehensive Cancer Center."Protein Expression Profile Analysis of Human Breast Cancer Progression by Use of High Density Tissue Microarrays".

Susan G. Komen Breast Cancer Foundation (Newman, L.) 4/02/03-9/30/04Role: Co-investigator $79,948 2%

Research Grant (Kleer, C.G.) 7/1/03-6/30/05John and Suzanne Munn Endowed Research Fund of the $25,000 0%University of Michigan Comprehensive Cancer Center.“Role of EZH2 in the Development of Breast Cancer and its Clinical Utility as a Novel Biomarker”



DAMD17-02-1-491 4/17/02-4/16/05USAMRMC-Clinical Bridge Award (Kleer, C.G.) $451,531 5%"Detection of Metastatic Potential in Breast Cancer by RhoC-GTPase and WISP3 Proteins"

DAMD17-02-1-0490 (Kleer, C.G.) 4/17/02-4/16/06USAMRMC-Career Development Award $355,152 13%"Detection of Metastatic Potential in Breast Cancer by RhoC-GTPase and WISP3 Proteins"The Career development and clinical bridge award were submitted together.

K08 CA090876-01A2 (Kleer, C.G.) 9/30/03-8/31/08NIH/NCI $678,800 80%"Role of LIBC (WISP3) in the Development of the Inflammatory Breast Cancer Phenotype"To investigate the role of WISP3 in the angiogenic switch, growth and invasion of inflammatory breast cancer.

N008211 Avon Foundation (Dontu, G.) 11/01/2006 - 10/31/2008 Changes Induced by Parity in the Stem/Progenitor Cell Population of the Normal Human BreastThe major goals of this project are to compare the size and functionality of the stem cell populations isolated from the breast mammary epithelium of nulliparous and parous women in order to assess possible correlations with different risks of breast cancer development.Role: Co-Investigator

CERTIFICATION AND LICENSURE

1994 ECFMG certified on July 11, 19941995 Board of Medicine, State of Michigan, June 19951997 Permanent Physician License, Board of Medicine,

State of Michigan. 4301065914, exp 1/31/2009

HONORS AND AWARDS

1993 University of Buenos Aires, School of Medicine, ranked among the best three students in class out of 1,000 medical students (AOA equivalent). December 1993

1993 Arthur Purdy Stout Society for Surgical Pathologist Travel Award1997 NIH Visiting Resident, Mentor: Dr. Maria J. Merino. National

Institutes of Health, National Cancer Institute, Bethesda, MD,July and August, 1997

1999 M.R. Abell House Officer Award. For outstanding achievement in pathology during residency training, A. James French Society of Pathologists.



2000 US Army Breast Cancer Research Program Concept Award2002 University of Michigan nominee for Culpeper Foundation Award2002 AACR Minority Scholar in Cancer Research Award2002 US Army Breast Cancer Research Program Career Development

and Clinical Bridge Awards2004 AACR Minority Scholar in Cancer Research Award2007- Harold A. Oberman Collegiate Professor of Pathology2008- Member, Education Committed, United States and Canadian

Academy of Pathology

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

1994-present American Medical Association, Member 1995-present American Society of Clinical Pathologists, Member1997-present College of American Pathologists, Member1999-present A. James French Society of Pathologists, Member2000-present United States and Canadian Academy of Pathology (USCAP), Member2000-present American Association for Cancer Research (AACR), Member2002-present CCN Proteins Society, Member2004-present Southwest Oncology Group (SWOG), Full Group Member2004-present American Society for Investigative Pathology (ASIP), Member2004-present American Society for Clinical Oncology (ASCO), Member

COMMITTEE AND ADMINISTRATIVE SERVICE

1999-present Lead Breast Pathologist, involved in the planning and coordination of the breast pathology service and quality assurance.

2002-present Member of the Breast Care Center Task Force to improve the care of patients with breast cancer, University of Michigan.

2002-2003 Member of the Steering Committee for the Cancer and Aging Initiative, University of Michigan.

2000-present Director, Specialized Training in Breast Pathology, University of Michigan.

2003-present Medical School Admissions Committee, University of Michigan.2004-2005 Pathology Graduate Student Admissions Committee, University of

Michigan.2005-present Pathology Graduate Program Executive Committee, University of

Michigan.2006-present Michigan Cancer Consortium Breast Cancer Advisory Committee,

Michigan Department of Community Health2006- present Member, College of American Pathologists Breast Cancer

Committee2008- present Member, Cancer Research Committee, UM Comprehensive Cancer

Center2008- present Member, Education Committee, United States and Canadian Academy of Pathology



TEACHING ACTIVITIES

Courses and Lectures

1990-93 Medical Student Histology Lab, Teaching Assistant, University of Buenos Aires School of Medicine

1996-98 Second Year Medical Student Pathology Labs, University of Michigan1999-present Breast Pathology lecture series to Pathology Residents.

Two, 1 hour didactic lecture on breast pathology per year.2000-2008 Fourth Year Medical Students Pathology-Radiology Course2001-present Fourth Year Medical Students Mentoring in Pathology

Consists of mentoring M4 students rotating in the Breast Pathology Sign out service.

4/2004-present Yearly ASCP Resident Review Course on Breast Pathology, American Society for Clinical Pathologists, Chicago, IL.

4/2005 Multi-disciplinary Conference, Mock Breast Tumor Board. Reproduction 611, M2 Reproduction Sequence 2005. University of Michigan.

Mentoring Faculty and Fellows

2001-present Breast Surgical Oncology Fellow for one month per year on breast pathology.

2002-2003 Peter C. Lucas, M.D., Ph.D., junior faculty member in the Department of Pathology specializing in Breast Pathology, (currently Assistant Professor of Pathology, University of Michigan).

2002-2003 Yiran Dai, M.D., junior faculty member in the Department of Pathology specializing in Breast Pathology (currently Assistant Professor, SUNY, NY).

7/2003-6/2004 Meryem Koker, M.D., Breast Pathology Fellow.7/2004-6/2005 David Sturtz, M.D., Breast Pathology Fellow.7/2005-6/2006 Anthony Kubat, M.D., Breast Pathology Fellow.7/2005-6/2006 Masood Siddiqui, M.D., Breast Pathology Fellow.5/2006- present Wei Huang, M.D., Ph.D, Post-Doctoral Fellow7/2006- 6/2007 Michael J. Hayes, M.D., Breast Pathology Fellow7/2007- present Maria Braman, M.D., Breast Pathology Fellow9/2007- present Anupama Pal, Ph.D., Post-Doctoral Fellow7/2008-6/2009 Cynthia Cookingham, M.D., Breast Pathology Fellow7/2009-present Julie Jorns, M.D., Breast Pathology Fellow

Medical, Graduate, and Undergraduate Students

2001-2002 Tammy Chang, undergraduate pre-med major, honors research project: “VEGF-C Expression in Breast Cancer Development”. Currently M4 student at University of Michigan.



6/2003-8/2003 Natalie Whitfield, M.S., Pathology Graduate Student in Molecular Biology.

5/2004-6/2005 Sara Monroe, second year graduate student in the Department of Pathology at University of Michigan.

6/2005-8/2005 Iris Wei, M2 student at University of Michigan.6/2006-6/2008 Anchi Lo, Graduate Student at School of Public Health, University of

Michigan.6/2006-4/2009 Sharon Hensley-Alford, Graduate Student at School of Public Health,

University of Michigan.2007- present Matthew DuPrie, Undergraduate Research Opportunity Student,

University of Michigan.2008-present Heather Krueger, Cellular and Molecular Biology (CMB) program

student, University of Michigan.2009 Glen Wozniak, Undergraduate Student, University of Michigan.4/2009-9/2009 Guadalupe Lorenzatti, Visiting Graduate Student from the Facultad of

Ciencias Quimicas (Chemical Sciencies), Universidad Nacional de Cordoba, Argentina

Dissertation Committees

2004-2007 Member of the Thesis Dissertation Committee for Neali Hendrix (Pathology Ph.D. candidate). Mentor: Kathleen Cho, Pathology Dept.

2005-2008 Member of the Thesis Dissertation Committee for Lisa Privette (Human Genetics Ph.D. candidate). Mentor: Liz Petty, Human Genetics Dept.

2006 Member of the thesis Dissertation Committee for Yuan Zheng. Mentor: Debashis Ghosh, Biostatistics Dept.

Preliminary Examination Committees

2005 Sara Monroe, Mentor: Celina Kleer, Cellular and Molecular Pathology2006 Barry Taylor, Mentor: Arul Chinnaiyan, Bioinformatics Dept.2006 Yuan Zheng, Mentor: Debashis Ghosh, Biostatistics Dept.

INVITED PRESENTATIONS

1. “Ulcerative Colitis-Does Traditional Teaching Still Hold?”James French Society of Pathologists, 6th Biennial Scientific Meeting,Rackham Amphitheater, 1999. Ann Arbor, MI.

2. “Detection of Metastatic Potential in Breast Cancer by RhoC-GTPase and WISP3 Proteins” MD Anderson Cancer Center, Houston, TX, March 8th, 2002.

3. “Role of RhoC in the Detection of Aggressive Breast Cancer” The World Congress in Breast Cancer, Victoria, Canada, June 7th, 2002.



4. “WISP3, a Tumor Suppressor Gene of Inflammatory Breast Cancer, Binds to IGF-I and Modernulates IGF Signaling” Meeting of the International CCN Society, Saint Malo, France, October 21st, 2002.

5. “The Polycomb Group Protein EZH2 is Involved in Breast Cancer Progression” Breast Oncology Meeting, University of Michigan, November 5, 2002.

6. “Difficult Diagnoses in Breast Pathology” VA Hospital, Ann Arbor, MI, November 21st, 2002.

7. “Characterization of RhoC, WISP3 and EZH2 as Markers of Aggressive Breast Cancer” Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, February 25th, 2003.

8. “Characterizing Aggressive Breast Cancer Phenotypes: From Biology to Biomarkers” Cancer Center Grand Rounds, University of Michigan, March 14th, 2003.

9. “The Differential Diagnosis of Hyperplastic Proliferations of the Breast” Twentieth MLabs Symposium, “The Harold Oberman Symposium on Breast Pathology” University of Michigan, May 17th, 2003.

10. “Practical Issues in Breast Pathology” Genesys Regional Medical Center, Grand Blanc, MI, October 22nd, 2003.

11. “Lobular Neoplasia: Pathologic Diagnosis and Clinical Implications” Department of Pathology Grand Rounds, St. Joseph Mercy Hospital, Ann Arbor, MI, November 24th, 2003.

12. “Pathologic and Molecular Prognostic Factors in Breast Cancer” Breast Cancer Educational Forum, University of Michigan Cancer Center, February 4th, 2004.

13. “Breast Cancer: The Role of the Pathologist in Diagnosis and in the Laboratory” Undergraduate Bioscience Program, University of Michigan Undergraduate School, February 4th, 2004.

14. “The Critical Role of the Pathologist in Delineating the Prognosis of Breast Cancer Patients” 2nd Annual Contemporary Issues in Multidisciplinary Breast Cancer Management, Ritz Carlton, Dearborn, MI, June 12th, 2004.

15. “Role of EZH2 in the Development of Breast Cancer” Breast Cancer Think Tank, Curacao, January 16th-22nd, 2005.

16. “The Pathologist Role in Breast Cancer Decision Making Process”, International Symposium on Breast Cancer, Tianjin, China, April 17-19, 2005.

17. “Molecular Determinants of inflammatory Breast Cancer” Beijing institute of Biotechnology, Beijing, China, April 20, 2005.



18. “Characterizing Aggressive Breast Cancer Phenotypes: From Biology to Biomarkers” Elizabeth Copeland Hem/ONC Grand Rounds, Henry Ford Hospital, March 25th, 2005.

19. “Inflammatory Breast Cancer: Pathology, Epidemiology and Molecular Genetics” Mayo Clinic Department of Pathology and Laboratory Medicine Centennial Celebration. Mayo Clinic, Rochester, MN. October 1st-2nd, 2005.

20. “Inflammatory Breast Cancer: Pathology and Molecular Determinants” Fourth Annual Pathology Research Symposium, University of Michigan League, November 4th, 2005.

21. “The role of CCN6 (WISP3) in breast tumorigenesis” The Burroughs Wellcome Fund, NC, February 8th, 2006.

22. “The Pathology of High Risk Breast Lesions” Michigan Radiological Society, Plymouth, MI, October 29th, 2006.

23. “The Pathology and Biology of Metaplastic Carcinomas of the Breast” Frontiers in Surgical Pathology, University of Michigan, Ann Arbor, September 2007.

24. “A novel role for CCN6 (WISP3) in Breast Cancer” Pathology Research Seminar Series, Department of Pathology, University of Michigan, Ann Arbor, December 2007.

25. “EZH2 emerges as a regulator of cell cycle progression in breast epithelial cells” Breast Oncology Program retreat, University of Michigan, Ann Arbor, April 11, 2008.

26. "Inflammatory Breast Cancer: Genetic alterations and Novel Tissue Biomarkers" CCNE Distinguished Lectureship at the "Frontiers of Cancer Nanotechnology Seminar Series” at Emory University and the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech University, May 2nd, 2008.

27. "WISP3 and RhoC as Determinants of Inflammatory Breast Cancer and as a Novel Tissue Biomarkers”, Invited speaker at the Department of Cell & Developmental Biology Seminar Series, Biomedical Sciences Research Building, University of Michigan, May 28, 2008.

28. “Insights into CCN6 function in Breast Tumorigenesis”, Visiting Professor at the Department of Pathology, Wayne State University, Detroit, MI, November 15, 2008.

29 Moderator at USCAP Breast Pathology Platform Sessions, USCAP meeting, Boston March 7-12, 2009.



30. “Difficult Topics in Breast Pathology: Columnar Lesions and Micrometastasis” Distinguished Lecturer, 8th Congress of Mastology, Rosario, Argentina, April 24-25, 2009.

31. “Molecular Classification of Breast Cancer” Distinguished Lecturer, 8th Congress of Mastology, Rosario, Argentina, April 24-25, 2009.

32. “Breast Cancer and Genes: New molecular tests in the clinic” Distinguished Lecturer, 8th Congress of Mastology, Rosario, Argentina, April 24-25, 2009.

33. “Tumor suppressor functions of CCN6 in the Mammary Gland”, Distinguished Visiting Professor, Universidad National de Ciencias Quimicas, Universidad Nacional de Cordoba, Argentina.

34. "New insights into the function of EZH2 in Breast Tumorigenesis" Visiting Professor, Translational group, Department of Cancer Biology, UMass Worcester, May 13, 2009.

35. “Molecular Pathobiology of Breast Cancer” Lecture at the 2009 Summer Academy of the ASIP (American Society for Investigative Pathology), Arlington, VA, June 5-8, 2009.

BIBLIOGRAPHY

Completed Publications in Scientific JournalsPeer-Reviewed Publications

1. Kleer, C.G. , Unni, K.K., and McLeod, R.A. Epithelioid Hemangioendothelioma of Bone. American Journal of Surgical Pathology 20(11):1301-1311, 1996.

2. Goh, M., Kleer, C.G., Kielczewski, P., Wojno, K., Kyung Mann, K., and Oesterling, J.E. Autologous Blood Transfusion Prior to Anatomical Radical Retropubic Prostatectomy: Is It Necessary? Urology 49(4):569-574, 1997.

3. Kleer, C.G. and Oberman, H.A. Adenoid Cystic Carcinoma of the Breast: Value of Histologic Grading and Proliferative Activity. American Journal of Surgical Pathology 22(5):569-575, 1998.

4. Kleer, C.G. and Appelman, H.D. Ulcerative colitis: Patterns of involvement in Colorectal Biopsies and Changes with Time. American Journal of Surgical Pathology 22(8):983-989, 1998.

5. Carlson, K.L., Helvie, M.A., Roubidoux, M.A., Kleer, C.G., Oberman, H.A., Wilson T.E., Pollak, E.W., and Rochester, A.B. Relationship between Mammographic Screening intervals and Size and Histology of Ductal Carcinoma in Situ. American Journal Roentgenology 172:313-317, 1999.



6. Kleer, C.G. , Wojno, K.J., Fields, K., and Singleton, T.P. Detection of Estrogen Receptor in Carcinomas of the Breast Using Automated Immunohistochemistry. Journal of Applied Immunohistochemistry and Molecular Morphology 7(2):103-107, 1999.

7. Kim, B., Barnett, J.L., Kleer, C.G., Appelman, H.D. Endoscopic and Histological Patchiness in Treated Ulcerative Colitis. American Journal of Gastroenterology 94:3258-3262, 1999.

8. Kleer, C.G. , and Michael, C.W. Fine Needle Aspiration of Breast Carcinomas with Prominent Lymphocytic infiltrate. Diagnostic Cytopathology 23:39-42, 2000.

9. Kleer, C.G. , Giordano, T.J., and Merino, M.J. Squamous Cell Carcinoma of the Thyroid: An Aggressive Tumor Associated with the Tall Cell Variant of Papillary Thyroid Carcinoma. Modern Pathology 13(7):742-746, 2000.

10. Kleer, C.G. , Bryant, B., Giordano, T.J., Sobel, M.E., and Merino, M.J. Genetic Changes in Chromosome 1p and 17p in Thyroid Cancer Progression. Endocrine Pathology 11(2):137-143, 2000.

11. Kleer, C.G. , Van Golen, K., and Merajver, S.D. inflammatory Breast Cancer: Clinical Syndrome and Molecular Determinants. Breast Cancer Research 2:423-429, 2000.

12. Kleer, C.G. , Giordano, T.G., Braun, T., and Oberman, H.A. Pathologic, Immunohistochemical, and Molecular Features of Benign and Malignant Phyllodes Tumors of the Breast. Modern Pathology 14(3):185-190, 2001.

13. Kleer, C.G. , Van Golen, K.L., Braun, T., and Merajver, S.D. Persistent E-Cadherin Expression in inflammatory Breast Cancer. Modern Pathology 14:458-464, 2001.

14. Kleer, C.G. , Van Golen, K.L., Zhang, Y., Wu, Z-F, Rubin, M.A., and Merajver, S.D. Characterization of RhoC Expression in Benign and Malignant Breast Disease: A Potential New Marker for Small Breast Carcinomas with Metastatic Potential. American Journal of Pathology 160(2):579-584, 2002.

15. Kleer, C.G., Zhang, Y., Pan, Q., Van Golen, K.L., Wu, Z-F, and Merajver, S.D. WISP3 Is a Novel Tumor Suppressor Gene of inflammatory Breast Cancer. Oncogene 21:3172-3180, 2002.

16. Zhou, M., Chinnaiyan, A.M., Kleer, C.G., Lucas, P.C., and Rubin, M.A. Alpha-Methyl acyl-CoA Racemase: A Novel Tumor Marker Overexpressed in Several Human Cancers and Their Precursor Lesions. American Journal of Surgical Pathology 26(7):926-931, 2002.

17. Kleer, C.G. , Tseng, M.D., Gutsch, D.E., Rochford, A.R., Wu, Z-F, Joynt, L.K., Helvie, M.A., Chang, T., Van Golen, K.L., and Merajver, S.D. Epstein-Barr Virus Is Implicated in the Pathogenesis of Breast Fibroadenomas in Immunocompromised Hosts. Modern Pathology 15(7):759-764, 2002.



18. Pan, Q., Kleer, C.G., Van Golen, K.L., Irani, J., Bottema, K.M., Bais, C., De Carvalho, M., Mesri, E.A., Robins, D.M., Dick, R., Brewer, G.J. and Merajver, S.D. Copper Deficiency induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis. Cancer Research 62(17):4854-9, 2002.

19. Valdez, R., Thorson, J., Finn, W.G., Schnitzer, B., and Kleer, C.G. Lymphocytic Mastitis /Diabetic Mastopathy: A Molecular, Immunophenotypic, and Clinicopathologic

Evaluation of Eleven Cases. Modern Pathology 16:223-228, 2003.

20. Rao, D.S., Bradley, S.V., Kumar, P.D., Hyun, T.S., Saint-Dic, D., Oravecz-Wilson, K., Kleer, C.G., and Ross, T.S. Altered Receptor Trafficking in Huntingtin interacting Protein 1-Transformed Cells. Cancer Cell 3:471-482, 2003.

21. Sabel, M.S., Schott, A.F., Kleer, C.G., Merajver, S.D., Cimmino, V., Diehl, K.M., Hayes, D.F., Chang, A., and Pierce, L.J. Sentinel Node Biopsy Prior to Neoadjuvant Chemotherapy. American Journal of Surgery 186:102-105, 2003.

22. Pan, Q., Bao, L.W., Kleer, C.G., Brewer, G.J., and Merajver, S.D. Antiangiogenic Tetrathiomolybdate Enhances Doxorubicin Therapy Against Breast Carcinoma. Molecular Cancer Therapeutics 2:617-622, 2003.

23. Collisson, E.A., Kleer, C.G., Wu, M., De, A., Gambhir, S.V., Merajver, S.D., and Kolodney, M.S. Atorvastatin Prevents RhoC Isoprenylation, invasion and Metastasis in Human Melanoma Cells. Molecular Cancer Therapeutics 2:941-948, 2003.

24. Kleer, C.G.* , Cao, Q.*, Varambally, S.*, Shen, R., Ota, I., Tomlins, S.A., Ghosh, D., Sewalt, R.G., Otte, A.P., Hayes, D.F., Sabel, M.S., Livant, D., Weiss, S.J., Rubin, M.A. and Chinnaiyan, A.M.. EZH2 is a Marker of Aggressive Breast Cancer and Promotes Neoplastic Transformation of Breast Epithelial Cells. Proceedings of the National Academy of Sciences 100(20):11606-11, 2003.

25. Kowalski, P.J., Rubin, M.A. and Kleer, C.G. E-Cadherin Expression in Primary Carcinomas of the Breast and Its Distant Metastases. Breast Cancer Research 5:R217-R222, 2003.

26. Ray, M.E., Yang, Z.Q., Albertson, D., Kleer, C.G., Washburn, J.G., Macoska, J.A., and Ethier, S.P. Genomic and Expression Analysis of the 8p11-12 Amplicon in Human Breast Cancer Cell Lines. Cancer Research 64(1):40-47, 2004.

27. Van Den Eynden, G.G., Van Der Auwera, I., Van Laere, S., Colpaert, C.G., Van Dam, P., Merajver, S., Kleer, C.G., Harris, A.L., Van Marck, E.A., Dirix, L.Y., and Vermeulen, P.B. Validation of a Tissue Microarray to Study Differential Protein Expression in Inflammatory and Non-inflammatory Breast Cancer. Breast Cancer Research and Treatment 85(1):13-22, 2004.



28. Kleer, C.G., Zhang, Y., Pan, Q., and Merajver, S.D. WISP3 is a Secreted Tumor Suppressor Protein That Modulates IGF Signaling in inflammatory Breast Cancer. Neoplasia 6(2):179-85, 2004.

29. Koker, M. and Kleer, C.G. P63 Expression in Breast Cancer: A Highly Sensitive and Specific Marker of Metaplastic Carcinoma. American Journal of Surgical Pathology 28(11):1506-12, 2004.

30. Marcus, B., Arenberg, D., Kleer, C.G., Chepeha, D., Schmalbach, C., Pan, Q., Hanash, S., Kuick, R., Lee, J., Merajver, S.D., and Teknos, T.N. Prognostic Factors in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma: The Impact of Tumor-Associated Macrophages. Cancer 101(12):2779-87, 2004.

31. Roubidoux, M.A., Sabel, M.S., Bailey, J.E., Kleer, C.G., Klein, K.A., Helvie, M.A. Small (<2.0-cm) Breast Cancers: Mammographic and US Findings at US-guided Cryoablation-initial Experience. Radiology 233(3):857-67, 2004.

30. Kleer, C.G. , Zhang, Y., Pan, Q., Gallagher, G., Wu, M., Wu, Z.F., and Merajver, S.D. WISP3 and RhoC Guanosine Triphosphatase Cooperate in the Development of inflammatory Breast Cancer. Breast Cancer Research 6(2):R110-5, 2004.

31. Stearns, V., Gallagher, M.A., Kleer, C.G., Singh, B., Freedman, M., Haddad, B., Isaacs, C., Warren, R., Brown, M., Trock, B. and Hayes, D.F. A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk Using Biomarkers as Surrogate Endpoints for Activity. Clinical Cancer Research 10(24):8332-40, 2004.

32. Pu, R.T., Schott, A.F., Sturtz, D.E., Griffith, K.A., and Kleer, C.G. Pathologic Features of Breast Cancer Associated with Complete Response to Neoadjuvant Chemotherapy: Importance of Tumor Necrosis. American Journal of Surgical Pathology 29(3):354-58, 2005.

33. Witniewicz, A., Shen, R., Lnu, S., Mehra, R., Chinnaiyan, A.M., Sabel, M.S., Rubin, M.A., and Kleer, C.G. Alpha Methyl acyl-CoA Racemase (AMACR) Protein Expression is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis. Cancer Epidemiology, Biomarkers, and Prevention 14(6):1418-23, 2005. Cover Article.

34. Khan, A., Sabel, M.S., Nees, A., Diehl, K.M., Cimmino, V.M., Kleer, C.G., Schott, A.F., Hayes, D.F., Chang, A.E., and Newman, L.A. Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients with Ultrasonography and Sentinel Lymph Node Biopsy. Annuals of Surgical Oncology 12(9):1-8, 2005.

35. Schott, A.F., Roubidoux, M.A., Helvie, M.A., Hayes, D.F., Kleer, C.G., Newman, L.A., Pierce, L.J., Griffith, K.A., Murray, S., Hunt, K.A., Paramagul, C., and Baker, L.H. Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy. Breast Cancer 92(3):231-8, 2005.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16079956&query_hl=1

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16079956&query_hl=1



36. Kleer, C.G. , Griffith, K., Sabel, M.S., Van Golen, K.L., Gallagher, G., Wu, Z.F., and Merajver, S.D. RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive Carcinomas of the Breast. Breast Cancer Research and Treatment 93(2):101-10, 2005.

37. Pan, Q., Bao, L.W., Kleer, C.G., Sabel, M., and Merajver, S.D. Protein Kinase C is Elevated in High Grade Breast Cancer and a Novel Target for RNA interference Anticancer Therapy. Cancer Research 65(18):8366-71, 2005.

38. Zeidler, M., Varambally, S., Cao, Q., Chinnaiyan, A.M., Ferguson, D.O., Merajver, S.D., and Kleer, C.G. The Polycomb Group Protein EZH2 Impairs DNA Repair in Human Mammary Epithelial Cells. Neoplasia 7(11):1011-9, 2005. Featured article and Cover.

39. Zhang, Y., Pan, Q., Zhong, H., Merajver, S.D., and Kleer, C.G. Inhibition of CCN6 (WISP3) Expression Promotes Neoplastic Transformation and Enhances the Effects of IGF-1 on Breast Epithelial Cells. Breast Cancer Research 7(6):R1080-9, 2005.

40. Mehra, R., Varambally, S., Shen, R., Ding, L., Sabel, M.S., Ghosh, D., Chinnaiyan, A.M.*, and Kleer, C.G*. Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-Analysis. Cancer Research 65(24):11259-64, 2005.

41. Krop, I., März, A., Carlsson, H., Li, X., Bloushtain-Qimron, N., Hu, M., Gelman, R., Sabel, M.S., Schnitt, S., Ramaswamy, S., Kleer, C.G., Enerbäck, C., and Polyak, K. A Putative Role for Psoriasin in Breast Tumor Progression. Cancer Research 65(24):11326-34, 2005.

42. Paramagul CP, Helvie MA, Robidoux MA, Kleer CG, Newman LA. Lobular carcinoma in situ (LCIS): Clinical and mammography findings of subsequent breast cancers. Journal of Women’s Imaging 7(4):181-189, 2005.

43. Ben-David, M.A., Kleer, C.G., Paramagul, C., Griffith, K.A., and Pierce, L.J. Is LCIS a Component of Breast Cancer a Risk Factor for Local Failure Following Breast- Conserving Therapy? Results of a Matched Pair Analysis. Cancer 106(1):28-34, 2006.

44. O’Malley, F.P., Mohsin, S.K., Badve, S., Bose, S., Collins, L.C., Ennis, M., Kleer, C.G., Pinder, S.E., and Schnitt, S.J. interobserver Reproducibility in the Diagnosis of Flat Epithelial Atypia of the Breast. Modern Pathology 19(2):172-9, 2006.

45. Newman, E.L., Kahn, A., Diehl, K.M., Cimmino, V.M., Kleer, C.G., Chang, A.E., Newman, L.A., and Sabel, M.S. Does the Method of Biopsy Affect the Incidence of Sentinel Lymph Node Metastases? The Breast Journal 12(1):53-57, 2006.

46. Ding, L., Erdmann, C., Chinnaiyan, A.M., Merajver, S.D., and Kleer, C.G. Identification of EZH2 as a Molecular Marker for a Precancerous State in Morphologically Normal Breast Tissues. Cancer Research 66(8):4095-9, 2006. Selected as a Cancer Research Highlight.



47. Hird, R.B., Chang, A., Cimmino, V., Diehl, K., Sabel, M., Kleer, C .G ., Helvie, M., Schott, A., Young, J., Hayes, D., Newman, L. Impact of estrogen receptor expression and other clinico pathologic features on tamoxifen use in ductal carcinoma in situ. Cancer 15;106:2113-8, 2006.

48. Kuefer, R., Day, K.C., Kleer, C.G., Sabel, M.S., Hofer, M.D., Varambally, S., Zorn, C.S., Chinnaiyan, A.M., Rubin, M.A., Day, M.L. The ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia 8(4): 319-329, 2006.

49. Newman, EA, Guest AB, Helvie MA, Roubidoux MA, Chang AE, Kleer CG, Diehl KM, Cimmino VM, Pierce L, Hayes D, Newman LA, Sabel MS. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer, 22;107(10):2346-2351, 2006.

50. Kleer, C.G ., Teknos, T.N., Islam, M., Marcus, B., Lee, J.S.J., Pan, Q., and Merajver, S.D. RhoC-GTPase Expression as a Potential Marker of Lymph Node Metastasis in Squamous Cell Carcinomas of the Head and Neck. Clinical Cancer Res, 12(15):4485-90, 2006.

51. Ding L, and Kleer CG. Enhancer of zeste 2 as a Marker of Preneoplastic Progression in the Breast. Cancer Res. 66(19)9352-5, 2006.

52. Zeidler M, and Kleer CG. The Polycomb Group Protein Enhancer of Zeste 2: Its Links to DNA Repair and Breast Cancer. J Mol Histol. 37(5-7):219-223, 2006.

53. Kunju L, and Kleer CG. Significance of Flat Epithelial Atypia on Mammotome Core Needle Biopsy: Should it be Excised? Hum Pathol. 38(1):35-41, 2007.

54. Maturen, K.E., Paramagul, C.P., Roubidoux, M.A., Kleer, C.G., Weadock W.J., Abate, S.A. Interactive Computer Teaching Module for Radiologic-Pathologic Correlations in Breast Imaging. MedEdPORTAL, In press.

55. Ostrander J.H., Daniel A.R., Lofgren K, Kleer CG and Lange CA. Breast Tumor Kinase (Brk/PTK6) Regulates Heregulin-Induced Activation of Erk5 and p38 MAP Kinases in Breast Cancer Cells. Cancer Research 67(9):4199-209, 2007.

56. Newman EA, Sabel MS, Nees AV, Schott A, Diehl KM, Cimmino VM, Chang AE, Kleer C, Hayes DF, Newman LA. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol. 14(10):2946-52, 2007.

57. Kleer CG, Zhang Y, Merajver SD. CCN6 (WISP3) as a New Regulator of the Epithelial Phenotype in Breast Cancer. Cells Tissues Organs. 185:95 - 99, 2007.

58. Privette LM, Gonzalez ME, Ding L, Kleer CG and Petty EM. Altered Expression of the Early Mitotic Checkpoint Gene, CHFR, in Breast Cancers: Implications for Tumor Suppression. Cancer Research, 67: 6064-74, 2007.

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17514407&ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Newman+L%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Hayes+D%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Young+J%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Schott+A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Helvie+M%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Kleer+C%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Sabel+M%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Diehl+K%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Cimmino+V%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Chang+A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Hird+RB%22%5BAuthor%5D



59. McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD. Expression of polycomb group protein EZH2 in nevi and melanoma. Journal of Cutaneous Pathology 34(8):597-600, 2007.

60. Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D.The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene, 26(49):7058-66, 2007.

61. Zakaria S, Degnim AC, Kleer CG, Diehl KA, Cimmino VM, Chang AE, Newman LA, Sabel MS. Sentinel lymph node biopsy for breast cancer: How many nodes are enough? J Surg Oncol, 96(7):554-9, 2007.

62. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC, Schall TJ.CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 104(40):15735-40, 2007.

63. Ginestier C, Hur MH, Charafe-Jauffret E., Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes DF, Birnbaum D, Wicha MS, Dontu G.ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell 1: 555-567, 2007.

64. Kleer CG *, Lo AC*, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Douglas JA, Alford SH, Merajver SD, Soliman AS. Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. Breast Cancer Res Treat. 112(1):141-7, 2008.

65. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS.BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 105(5):1680-5, 2008.

66. Huang W, Zhang Y, Varambally S, Chinnaiyan AM, Banerjee M, Merajver SD, and Kleer CG. Inhibition of CCN6 (WISP3) down-regulates E-cadherin in the breast epithelium through induction of Snail and ZEB1. American Journal of Pathology 172:893-904, 2008.

67. Hayes, MJ*, Thomas, D*, Emmons A, Giordano TJ, and Kleer, CG. Genetic Changes of Wnt Pathway Genes are Common Events in Metaplastic Carcinomas of the Breast. Clinical Cancer Research 14(13):4038-44, 2008.

68. Kunju L, Ding Y, Kleer CG. Convergence between breast flat epithelial atypia and atypical ductal hyperplasia: validity and limitations. Human Pathol. Sept 15, 2008.

69. Kleer CG *, Bloushtain-Qimron N*, Chen Y-H, Carrasco D, Hu M, Yao J, Kraeft S, Collins LC, Sabel MS, Argani P, Gelman R, Schnitt SJ, Krop IE, Polyak K. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clinical Cancer Research, 14: 5357-5367, 2008.

http://www.ncbi.nlm.nih.gov/pubmed/18230721?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum










70. Kunju LP, Ding Y, and Kleer CG. Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: Comparison of flat epithelial atypia and other intra-epithelial lesions. Pathology International 58(10):620-5, 2008.

71. Kilbride KE, Lee MC, Nees AV, Cimmino VM, Diehl KIM, Sabel MS, Hayes DF, Schott AF, Kleer CG, Chang AE, Newman LA. Axillary staging Prior to Neoadjuvant Chemotherapy for Breast Cancer: Predictors of Recurrence. Ann Surg Oncol. 15(11):3252-8, 2008.

72. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27(58):7274-84, 2008.

73. Sabel MS, Rogers K, Griffith K, Jagsi R, Kleer CG, Diehl KA, Breslin TM, Cimmino VM, Chang AE, Newman LA. Residual disease after re-excision lumpectomy for close margins. J Surg Oncol. 99(2):99-103, 2009.

74. Gonzalez ME, Li X, Toy K, DuPrie M, Banerjee M, Ljungman M, Merajver SD, Kleer CG. Downregulation of Enhancer of Zeste-2 decreases growth of estrogen receptor negative invasive breast carcinoma and requires BRCA1. Oncogene 28(6):843-53, 2009.

75. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Weaver DL, Winer E; Members of the Cancer Committee, College of American Pathologists. Protocol for examination of specimens from patients with ductal carcinoma in situ of the breast. Arch pathol Lab Med. 133(1):15-25, 2009.

76. Lo AC, Georgopoulos A, Kleer CG, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Omar HG, Douglas JA, Merajver SD, Soliman AS. Analysis of RhoC expression and lymphovascular emboli in inflammatory vs. non-inflammatory breast cancers in Egyptian patients. Breast 18(1):55-9, 2009.

77. Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Merajver S, Sebti SM. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphammide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res 15(8):2942-8, 2009.

78. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174(6):2023-34, 2009.

79. Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, Jasmin JF, Frank PG, Pestell RG, Kleer CG, Sotgia F, Lisanti MP. Towards a new “stromal-based” classification system for human breast cancer prognosis and therapy. Cell Cycle 8(11):1654-8.

80. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, Rehemtulla A, Kleer CG, Hayes DF, Lucas PC,



Varambally S, Chinnaiyan AM. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA 106(25):10284-9, 2009.

81. Li X, Gonzalez ME, Toy K, Filzen T, Merajver SD and Kleer CG. Targeted Overexpression of EZH2 in the Mammary Gland Disrupts Ductal Morphogenesis and Causes Epithelial Hyperplasia. Am J Pathol, In press.

82. Kleer CG. Carcinoma of the Breast with Medullary-Like Features: Roles of BRCA1 and EZH2. Arch Pathol Lab Med, In press.

83. Kleer CG. Pathology re-review as an essential component of breast cancer management. Current Oncology, In press.

* equal contribution

Non-peer reviewed publications

1. Kleer, C.G. and Merajver, S.D. The Pathology of Familial Breast Cancer: Predictive Value of Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients with Mutations in BRCA1 and BRCA2. The American Journal of Oncology Review 1(4):194-195, 2002.

Book Chapters

1. Feldstein, C.G. (Kleer) , Romero, J.C., Ruilope, L., Lahera, V. Humoral Regulation of Glomerular Hemodynamics in Hypertension. Molecular Cell Biology of Cardiovascular Diseases 86-95. Mosby/Doyma, Libros, Madrid, Spain, 1995.

2. Kleer, C.G. and Appelman, H.D. Surgical Pathology of Crohn’s Disease. Surgical Clinics of North America 81(1):13-30, Vii, Feb 2001.

3. Kleer, C.G. , Ding, L. WISP3 (WNT-1 inducible Signaling Pathway Protein 3). Atlas Genet Cytogenetic Oncology Hematology, Mar 2005.

4. Kleer, C.G. Polycomb Group Proteins. Encyclopedia of Cancer, Second Edition 2007. Editor: Manfred Schwab. Springer-Verlag, Germany.

5. Kleer, C.G. CCN6 (WISP3) as a regulator of EMT: Implications in breast cancer metastasis. Human Epithelial Tumor Cell Plasticity: Implications for Cancer Progression and Metastasis 59-68.Editor: Paul J. Higgins. Research Signpost, India, 2008.

6. Pal A, Huang W, Kleer, C.G. CCN6 as a modulator of growth factor signaling pathways: implications for breast cancer growth and invasion. Proceedings of the CCN Society, in press.



7. Kleer, C.G. , and Sabel MS. Prognostic and Predictive Factors in Breast Cancer. In Kuerer’s Breast Surgical Oncology, 2nd Edition (editor, Henry Kuerer, MD, PhD, FACS) McGraw-Hill Professional, New York, in press.

Oral and Poster Presentations

Kleer, C.G., and Oberman, H.A. Adenoid Cystic Carcinoma of the Breast: Value of Histologic Grading and Proliferative Activity. Modern Pathology 10:21A, 1997.

Kleer, C.G., and Appelman, H.D. Ulcerative Colitis: Patterns of Involvement in Colorectal Biopsies and Changes with Time. Modern Pathology 10:58A, 1997.

Goh, H., Kleer, C.G., Kielczewski, P., Wojno, K., Kyung Mann, K., and Oesterling, J.E. Autologous Blood Transfusion Prior to Anatomical Radical Retropubic Prostatectomy: Is It Necessary? Poster Presentation, American Urologic Association Meeting, New Orleans, LA, May 1997.

Kleer, C.G., Bryant, B., Giordano, T.G., Sobel, M.E., and Merino, M.J. Genetic Changes in Chromosome 1p and 17p in Thyroid Cancer Progression. Modern Pathology 11:57A, 1998.

Kleer, C.G., Giordano, T.J., and Merino, M.J. Squamous Cell Carcinoma of the Thyroid: An Aggressive Tumor Associated with Tall Cell Variant of Papillary Thyroid Carcinoma. Modern Pathology 11:57, 1998.

Kleer, C.G., Singleton, T.P., and Wojno, K.J. Estrogen Receptor Expression in Paraffin Embedded Carcinomas of the Breast: Comparison of Two Monoclonal Antibodies Using an Automated Stainer. American Journal of Clinical Pathology 109:488, 1998

Kim, B., Barnett, J.L., Kleer, C.G., and Appelman, H.D. Endoscopic and Histologic Patchiness in Treated Ulcerative Colitis. American Journal of Gastroenterology 93:1691, 1998.

Kleer, C.G., Giordano, T.J., Kleiner, D.E., and Merino, M.J. Role of p27kipl, Ki-67, and p53 as Diagnostic and Prognostic Markers in Thyroid Neoplasms. International Journal of Surgical Pathology. Poster Presentation, International Academy of Pathology, Nice, France, Oct. 1998.

Tseng, M.D., Gutsch, D.E., Helvie, M.A., Van Golen, K.L., Merajver, S.D., and Kleer, C.G. Epstein-Baar Virus is Implicated in the Pathogenesis of Breast Fibroadenomas in Immunocompromised Hosts. Proceedings of the American Association for Cancer Research, 41:74, 2000. Presented at the AACR meeting, San Francisco, CA, Apr. 2000.

Tan, L.C. and Kleer, C.G. E-cadherin, Gross Cystic Disease Fluid Protein-15 (gcdfp-15) and High Molecular Weight Cytokeratin Expression in In-situ Carcinomas of the Breast. Poster presentation at ASCP meeting, San Diego, CA, Oct. 2000.

Tan, L.C. and Kleer, C.G. HER2/neu Overexpression Does Not Predict Axillary Lymph Node Metastases in Invasive Lobular Carcinoma of the Breast. Modern Pathology 14(1):38A, 2001.



Tan, L.C., Thomas, D.G., Sanders, D., Mataverde, P., Baker, L., Giordano, T.J. and Kleer, C.G. Detection of Telomerase Catalytic Component (hTRT) in Invasive and In-situ Lobular Carcinomas of the Breast. Modern Pathology 14(1):38A, 2001.

Kowalski, P.J., Rubin, M.A. and Kleer, C.G. Reduced or Absent E-cadherin Expression Predicts Early Metastases in Breast Cancer. Modern Pathology 14(1):29A, 2001.

Kleer, C.G., Van Golen, K.L., Braun, T., and Merajver, S.D. Persistent E-cadherin Expression in Inflammatory Breast Cancer. Proceedings of the American Association for Cancer Research 42:894, 2001. Presented at the AACR meeting in New Orleans, LA, Mar 2001.

Kleer, C.G. and Rubin, M.A. Increased Expression of -methyl acyl-CoA racemase (AMACR) is Associated with Tumor Size and Lymph Node Metastases in Breast Cancer. Presented at the IAP meeting, Chicago, IL, Feb. 2002.

Valdez, R., Thorson, J., Finn, W.G., Schnitzer, B., and Kleer, C.G. Lymphocytic Mastitis/Diabetic Mastopathy: A Molecular, Immunophenotypic and Clinicopathologic Evaluation of Eleven Cases. Presented at the IAP meeting, Chicago, IL, Feb. 2002.

Kleer, C.G. and Afify, A.M. HER-2/neu Over-Expression: Comparison between Three Immunohistochemical Assays. Presented at the IAP meeting, Chicago, IL, Feb. 2002.

Kleer, C.G., Van Golen, K.L., Zhang, Y., Wu, Z-F, Rubin, M.A., and Merajver, S.D. RhoC Expression in Benign and Malignant Breast Disease: A Promising Marker of Metastatic Potential in Small Tumors. Presented at the AACR meeting, San Francisco, CA, Apr. 2002.

Pan, Q., Kleer, C.G., Van Golen, K.L., Irani, J., Bottema, K.M., Bais, C., De Carvalho, M., Mesri, E.A., Robins, D.M., Dick, R., Brewer, G.J., and Merajver, S.D. Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis. Presented at the AACR meeting, San Francisco, CA, Apr. 2002.

Kleer, C.G., Van Golen, K.L., Zhang, Y., Wu, Z-F, Rubin, M.A., and Merajver, S.D. RhoC Expression in Benign and Malignant Breast Disease: A Promising marker of Metastatic Potential in Small Tumors. ASCO meeting, Orlando, FL, May 18, 2002.

Kleer, C.G., Chang, T., Pan, Q., Rubin, M.A., Merajver, S.D. Characterization of VEGF-C Expression in Breast Tissues Using High Density Tissue Microarrays. Histopathology 41(1): 1-63. Oral presentation, International Academy of Pathology, Amsterdam, 2002.

Sturtz, D.E., Schott, A.F., and Kleer, C.G. Pathologic Features of Breast Cancer Associated with Complete Response to Neoadjuvant Chemotherapy: Importance of Histologic Type and Grade. Platform presentation, USCAP meeting, Washington DC, 2003.



Kleer, C.G., Zhang, Y., Pan, Q., Merajver, S.D. Characterization of WISP3, A Novel Tumor Suppressor Gene for Inflammatory Breast Cancer, in Normal Breast and Breast Disease. Platform presentation, USCAP meeting, Washington DC, 2003.

Kleer, C.G., Shen, R., Wolf, J., and Rubin, M.A. Characterization of Platelet Derived Growth Factor Receptor Expression in Breast Cancer Identifies Inflammatory Breast Cancer as a Potential Target for Treatment with PDGF-b Inhibitors. Poster presentation, USCAP meeting, Washington DC, 2003.

Kleer, C.G., Shen, R., Chinnaiyan, A.M., and Rubin, M.A. EZH2 is Overexpressed During Breast Cancer Progression and is a Predictor of Poor Outcome in Patients with Breast Cancer. Poster presentation, USCAP meeting, Washington DC, 2003.

Kleer, C.G., Zhang, Y., Pan, Q., and Merajver, S.D. WISP3 is a Secreted Protein and Modulates IGF Signaling in Inflammatory Breast Cancer. Mini symposium AACR Meeting, Washington DC, July 11-14, 2003.

Koker, M. and Kleer, C.G. Metaplastic Carcinoma of the Breast: P63 is a Highly Sensitive and Specific Marker. Platform presentation, USCAP Meeting, Vancouver, BC, 2004.

Koker M., and Kleer, C.G. Smooth Muscle Actin and p63 in the Diagnosis of Difficult Lesions of the Breast. Poster presentation, USCAP Meeting, Vancouver, BC, 2004.

Koker, M., Griffith K., Newman, L., Sabel, M., Rubin, M.A., and Kleer, C.G. Pathologic Factors Predictive of Sentinel Lymph Node Metastasis in Patients with Breast Cancer. Poster presentation, USCAP Meeting, Vancouver, BC, 2004.

Witkiewicz, A., Rubin, M.A., and Kleer, C.G. AMACR Expression in Breast Adenocarcinomas. Poster presentation, USCAP Meeting, Vancouver, BC, 2004.

Kleer, C.G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S.A., Ghosh, D., Sewalt, R.G., Otte, A.P., Hayes, D.F., Sabel, M.S., Livant, D., Weiss, S.J., Rubin, M.A., and Chinnaiyan, A.M. EZH2 is a Marker of Aggressive Breast Cancer and Promotes Neoplastic Transformation of Breast Epithelial Cells. Platform presentation, USCAP Meeting, Vancouver, BC, 2004.

Kleer, C.G., Griffith, K., Sabel, S., Gallagher, G., Merajver, S.D. RhoC GTPase is a New Tissue Biomarker Predictive of Local Recurrence in Patients with Breast Cancer. Poster presentation, AACR meeting, Orlando, FL, 2004.

Zhang, Y., Monroe, S., Merajver, S.D., and Kleer, C.G. Inhibition of WISP3 (CCN6) Promotes the Neoplastic Transformation and Enhances the Effects of IGF-1 on Breast Epithelial Cells. Pathology Research Symposium, University of Michigan Pathology Graduate Program, Nov. 2004.

Kleer, C.G., Griffith, K., Sabel, M.S., Van Golen, K.L., Gallagher, G., Wu, Z.F., and Merajver, S.D. RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive



Carcinomas of the Breast. Poster Discussion Session, Breast Cancer Symposium, San Antonio, TX, Dec. 8-11, 2004.

Mehra, R., Chinnaiyan, A.M., and Kleer, C.G. GATA3 as a Novel Prognostic Marker for Breast Cancer. Platform presentation, USCAP meeting, San Antonio, TX, Feb 28- Mar 3, 2005.

Mohsin, S.K., Badve, S., Bose, S., Kleer, C.G., Pinder, S.E., and O’Malley, F. Assessment of Variability in Diagnosing ‘Atypia’ in Columnar Cell Lesions (CCL) of the Breast. Poster Session, USCAP meeting, San Antonio, TX, Feb 28-Mar 3, 2005.

Mehra, R., Varambally, S., Poisson, L.M., Rhodes, D.R., Ghosh, D., Chinnaiyan, A.M., and Kleer, C.G. Overexpression of Minichromosome Maintenance Protein 2 is Associated with Tumor Aggressiveness and Outcome in Breast Cancer. Platform presentation, USCAP meeting, San Antonio, TX, Feb 28- Mar 3, 2005.

Zhang, Y., Monroe, S., Merajver, S.D., and Kleer, C.G. Inhibition of WISP3 (CCN6) Promotes the Neoplastic Transformation and Enhances the Effects of IGF-1 on Breast Epithelial Cells. Era of Hope Meeting, Department of Defense Breast Cancer Research Program, Poster presentation, Philadelphia, PA, June 8-11, 2005.

Zhang, Y., Pan, Q., Zhong H., Merajver, S.D., and Kleer, C.G. Inhibition of WISP3 (CCN6) Promotes a Mesenchymal Phenotype and Enhances the Effects of IGF-1 on Breast Epithelial Cells. Epithelial Mesenchymal Transition (EMT) Conference. Vancouver, BC, Canada, October 1-3, 2005. Poster Presentation.

Wei, I.*, Pu, R.*, Zhang, Y., Merajver, S.D., and Kleer, C.G. Analysis of WISP3 Promoter Methylation in Inflammatory Breast Cancer. Student Biomedical Research Forum, University of Michigan Medical School, Ann Arbor, MI, Nov. 2005.

Hayes, M.J. and Kleer, C.G. Expression of the Undifferentiated Cell Marker P63 in Primary invasive Carcinomas of the Breast and Their Nodal Metastases. Laboratory Investigation 86(1): 29A. Presented at USCAP meeting, Atlanta, GA, Feb. 2006.

Kunju, L.P. and Kleer, C.G. Significance of Flat Epithelial Atypia (FEA) on Mammotome Core Needle Biopsy: Should It Be Excised? Laboratory Investigation 86(1): 32A. Presented at USCAP meeting, Atlanta, GA, Feb. 2006.

Zeidler, M., Varambally, S., Cao, Q., Chinnaiyan, A.M., Ferguson, D.O., Merajver, S.D., and Kleer, C.G. The Polycomb Group Protein EZH2 Impairs DNA Repair in Human Mammary Epithelial Cells. AACR meeting, April 1-5, 2006, Washington DC. Poster Presentation.

Wei, I.*, Pu, R.*, Zhang, Y., Merajver, S.D., and Kleer, C.G. Analysis of WISP3 Promoter Methylation in Inflammatory Breast Cancer. XXVI Congress of the International Academy of Pathology, Montreal, Sept. 16-21, 2006.



Hayes, MJ, Witkiewicz, A, Kleer, C.G. Aberrant b-Catenin Expression is Associated with Morphology and Prognosis in Metaplastic Mammary Carcinomas. United States and Canadian Academy of Pathology, San Diego, CA, March 24-30, 2007.

Kunju, LP, Kleer, C.G. Carcinoma and Grade 1 (Well Differentiated) Invasive Ductal Carcinoma: Comparision of Associated Flat Epithelial Atypia and Other Intra-Epithlial Lesions. United States and Canadian Academy of Pathology, San Diego, CA, March 24-30, 2007.

Lo, AC., Soliman, AS., Kleer, C.G, Alford, SH., Eissa, S., Hablas, A., Khaled, HM., Omar, S., Merajver, S. Molecular Epidemiologic Features of Inflamitory Breast Cancer: A Comparison Between Egyptian and U.S. Patients. AACR meetingApril 14-18, 2007, Los Angeles, CA.

Georgopolis, A., Soliman, A., Kleer, CG., Lo, AC., Eissa, S., Khaled, H., Omar, S., Merajver, SD. Molecular Differences Between Inflammatory Breast Cancers in Egyptian Patients. AACR meeting, April 14-18, 2007, Los Angeles, CA.

Huang W, Zhang Y, Varambally S, Chinnaiyan AM, Banerjee M, Merajver SD, and Kleer CG. Inhibition of CCN6 (WISP3) down-regulates E-cadherin in the breast epithelium through induction of Snail and ZEB1. AACR meeting, April 11-16, 2008, San Diego, CA

Gonzalez ME, Li, X, Toy K, duPrie M, Banerjee M, Lungman M, Merajver SD and Kleer CG. Enhancer of zeste 2 regulates breast cancer growth and proliferation through BRCA1. Minisymposium at AACR meeting, April 11-16, 2008, San Diego, CA

Hensley Alford S, Merajver SD, Gruber SB, Omer Gad H and Kleer CG. Epidemiology of EZH2 in aggressive early stage breast cancer. Poster Presentation at AACR Metastasis Conference, August 3-7, 2008, Vancouver, Canada.

Equal contribution

CURRICULUM VITAE

Documents

nih zrg1 obt

tumor suppressor gene

ad hoc reviewer

james french society

thesis dissertation committee

clinical bridge award

nih tumor progression

cancer research award